New clinical and translational data on pds biotechnology's novel investigational cancer therapies pds0101 and pds01adc to be presented at the 2025 society for immunotherapy of cancer (sitc) annual meeting

Three abstracts accepted for presentation, including one rapid oral abstract session presentations to highlight ongoing clinical and translational research across pds biotechnology's immunotherapy platforms princeton, n.j., oct. 30, 2025 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the national cancer institute (nci) will present new clinical data at the 2025 society for immunotherapy of cancer (sitc) annual meeting, taking place in national harbor, maryland.
PDSB Ratings Summary
PDSB Quant Ranking